Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. [electronic resource]
Producer: 20121022Description: 1263-4; author reply 1266-8 p. digitalISSN:- 1460-2105
- Antineoplastic Agents, Hormonal -- therapeutic use
- Breast Neoplasms -- drug therapy
- Cytochrome P-450 CYP2D6 -- genetics
- Female
- Glucuronosyltransferase -- genetics
- Humans
- Neoplasm Recurrence, Local -- epidemiology
- Nitriles -- therapeutic use
- Polymorphism, Single Nucleotide
- Postmenopause
- Tamoxifen -- therapeutic use
- Triazoles -- therapeutic use
No physical items for this record
Publication Type: Letter; Comment
There are no comments on this title.
Log in to your account to post a comment.